Table 1. Open in new tab Characteristics...

	Total	3TC+DTG	RPV+DTG	PI+DTG	3TC/ABC/DTG	TDF/FTC+DTG	TAF/FTC+DTG
Sex M, No. (%)	533 (74.7)	59 (78.7)	26 (57.8)	45 (75.0)	244 (74.8)	111 (75.0)	48 (81.4)	.12
Age, mean ± SD, y	47.2 ± 11.6	50.6 ± 11.1	51.8 ± 10.8	50.4 ± 11.3	46.9 ± 11.5	45.0 ± 11.2	43.8 ± 12.4	<.0001
Caucasian, No. (%)	648 (90.9)	69 (92.0)	43 (95.6)	55 (91.7)	294 (90.2)	139 (93.9)	48 (81.4)	.09
Weight, mean ± SD, kg	70.5 ± 13.4	73.3 ± 13.9	70.2 ± 13.3	70.4 ± 11.5	69.8 ± 13.1	70.6 ± 14.6	71.4 ± 13.0	.46
BMI (n = 608), mean ± SD, kg/m²	24.2 ± 4.0	24.5 ± 3.5	25.0 ± 3.8	24.2 ± 3.5	24.0 ± 4.0	24.0 ± 4.2	24.7 ± 4.3	.61
Risk factor for HIV acquisition, No. (%)
Sexual	513 (72.0)	59 (78.7)	33 (73.3)	39 (65.0)	245 (75.2)	85 (57.4)	52 (88.1)
IVDU	112 (15.7)	8 (10.7)	11 (24.2)	14 (23.3)	42 (12.8)	32 (21.6)	5 (8.5)	<.0001
Other	88 (12.3)	8 (10.7)	1 (2.2)	7 (11.7)	39 (12.0)	31 (21.0)	2 (3.4)
CD4, mean ± SD, cells/mL	570 ± 367	725 ± 422	699 ± 318	614 ± 317	617 ± 359	419 ± 330	364 ± 312	<.0001
CD4/CD8 (n = 616), median (IQR)	0.64 (0.34–0.99)	0.90 (0.57–1.23)	0.92 (0.62–1.14)	0.67 (0.50–0.97)	0.68 (0.41–1.03)	0.44 (0.17–0.74)	0.38 (0.11–0.67)	<.0001
Naïve, No. (%)	195 (27.4)	5 (6.7)	1 (2.2)	1 (1.7)	75 (23.0)	68 (45.9)	45 (76.3)	<.0001
CDC stage C, No. (%)	159 (22.3)	10 (13.3)	9 (20.0)	20 (33.3)	69 (21.2)	38 (25.7)	13 (22.0)	.07
HIV-RNA >50 copies/mL (experienced participants), No. (%)	95 (18.3)	6 (8.6)	1 (2.3)	22 (37.3)	39 (15.5)	24 (30.0)	3 (21.4)	<.0001
Years of ART (experienced participants), median (IQR)	9.8 (4.3–17.4)	10.8 (7.5–17.6)	12.1 (6.7–18.3)	13.5 (6.8–19.2)	7.9 (4.0–15.5)	9.2 (3.2–17.3)	9.1 (4.5–19.0)	.004
HCV active infection (baseline), No. (%)	66 (9.3)	2 (2.7)	2 (4.4)	7 (11.7)	27 (8.3)	25 (16.9)	3 (5.1)	.004
HCV eradication during follow-up (n = 66), No. (%)	30 (45.4)	0 (0)	1 (50.0)	3 (42.9)	15 (55.6)	10 (40.0)	1 (33.3)	.66
Statin use at baseline, No. (%)	65 (9.1)	11 (14.7)	7 (15.6)	9 (15.0)	26 (8.0)	9 (6.1)	3 (5.1)	.05
Statin started during the first year of observation (n = 648), No. (%)	17 (2.6)	2 (3.1)	3 (7.9)	2 (3.9)	6 (2.0)	3 (2.2)	1 (1.8)	.38

Total

3TC+DTG

RPV+DTG

PI+DTG

3TC/ABC/DTG

TDF/FTC+DTG

TAF/FTC+DTG

n = 713

n = 75

n = 45

n = 60

n = 326

n = 148

n = 59

Sex M, No. (%)

533 (74.7)

59 (78.7)

26 (57.8)

45 (75.0)

244 (74.8)

111 (75.0)

48 (81.4)

.12

Age, mean ± SD, y

47.2 ± 11.6

50.6 ± 11.1

51.8 ± 10.8

50.4 ± 11.3

46.9 ± 11.5

45.0 ± 11.2

43.8 ± 12.4

<.0001

Caucasian, No. (%)

648 (90.9)

69 (92.0)

43 (95.6)

55 (91.7)

294 (90.2)

139 (93.9)

48 (81.4)

.09

Weight, mean ± SD, kg

70.5 ± 13.4

73.3 ± 13.9

70.2 ± 13.3

70.4 ± 11.5

69.8 ± 13.1

70.6 ± 14.6

71.4 ± 13.0

.46

BMI (n = 608), mean ± SD, kg/m²

24.2 ± 4.0

24.5 ± 3.5

25.0 ± 3.8

24.2 ± 3.5

24.0 ± 4.0

24.0 ± 4.2

24.7 ± 4.3

.61

Risk factor for HIV acquisition, No. (%)

Sexual

513 (72.0)

59 (78.7)

33 (73.3)

39 (65.0)

245 (75.2)

85 (57.4)

52 (88.1)

IVDU

112 (15.7)

8 (10.7)

11 (24.2)

14 (23.3)

42 (12.8)

32 (21.6)

5 (8.5)

<.0001

Other

88 (12.3)

8 (10.7)

1 (2.2)

7 (11.7)

39 (12.0)

31 (21.0)

2 (3.4)

CD4, mean ± SD, cells/mL

570 ± 367

725 ± 422

699 ± 318

614 ± 317

617 ± 359

419 ± 330

364 ± 312

<.0001

CD4/CD8 (n = 616), median (IQR)

0.64 (0.34–0.99)

0.90 (0.57–1.23)

0.92 (0.62–1.14)

0.67 (0.50–0.97)

0.68 (0.41–1.03)

0.44 (0.17–0.74)

0.38 (0.11–0.67)

<.0001

Naïve, No. (%)

195 (27.4)

5 (6.7)

1 (2.2)

1 (1.7)

75 (23.0)

68 (45.9)

45 (76.3)

<.0001

CDC stage C, No. (%)

159 (22.3)

10 (13.3)

9 (20.0)

20 (33.3)

69 (21.2)

38 (25.7)

13 (22.0)

.07

HIV-RNA >50 copies/mL (experienced participants), No. (%)

95 (18.3)

6 (8.6)

1 (2.3)

22 (37.3)

39 (15.5)

24 (30.0)

3 (21.4)

<.0001

Years of ART (experienced participants), median (IQR)

9.8 (4.3–17.4)

10.8 (7.5–17.6)

12.1 (6.7–18.3)

13.5 (6.8–19.2)

7.9 (4.0–15.5)

9.2 (3.2–17.3)

9.1 (4.5–19.0)

.004

HCV active infection (baseline), No. (%)

66 (9.3)

2 (2.7)

2 (4.4)

7 (11.7)

27 (8.3)

25 (16.9)

3 (5.1)

.004

HCV eradication during follow-up (n = 66), No. (%)

30 (45.4)

0 (0)

1 (50.0)

3 (42.9)

15 (55.6)

10 (40.0)

1 (33.3)

.66

Statin use at baseline, No. (%)

65 (9.1)

11 (14.7)

7 (15.6)

9 (15.0)

26 (8.0)

9 (6.1)

3 (5.1)

.05

Statin started during the first year of observation (n = 648), No. (%)

17 (2.6)

2 (3.1)

3 (7.9)

2 (3.9)

6 (2.0)

3 (2.2)

1 (1.8)

.38

	Total	3TC+DTG	RPV+DTG	PI+DTG	3TC/ABC/DTG	TDF/FTC+DTG	TAF/FTC+DTG
Sex M, No. (%)	533 (74.7)	59 (78.7)	26 (57.8)	45 (75.0)	244 (74.8)	111 (75.0)	48 (81.4)	.12
Age, mean ± SD, y	47.2 ± 11.6	50.6 ± 11.1	51.8 ± 10.8	50.4 ± 11.3	46.9 ± 11.5	45.0 ± 11.2	43.8 ± 12.4	<.0001
Caucasian, No. (%)	648 (90.9)	69 (92.0)	43 (95.6)	55 (91.7)	294 (90.2)	139 (93.9)	48 (81.4)	.09
Weight, mean ± SD, kg	70.5 ± 13.4	73.3 ± 13.9	70.2 ± 13.3	70.4 ± 11.5	69.8 ± 13.1	70.6 ± 14.6	71.4 ± 13.0	.46
BMI (n = 608), mean ± SD, kg/m²	24.2 ± 4.0	24.5 ± 3.5	25.0 ± 3.8	24.2 ± 3.5	24.0 ± 4.0	24.0 ± 4.2	24.7 ± 4.3	.61
Risk factor for HIV acquisition, No. (%)
Sexual	513 (72.0)	59 (78.7)	33 (73.3)	39 (65.0)	245 (75.2)	85 (57.4)	52 (88.1)
IVDU	112 (15.7)	8 (10.7)	11 (24.2)	14 (23.3)	42 (12.8)	32 (21.6)	5 (8.5)	<.0001
Other	88 (12.3)	8 (10.7)	1 (2.2)	7 (11.7)	39 (12.0)	31 (21.0)	2 (3.4)
CD4, mean ± SD, cells/mL	570 ± 367	725 ± 422	699 ± 318	614 ± 317	617 ± 359	419 ± 330	364 ± 312	<.0001
CD4/CD8 (n = 616), median (IQR)	0.64 (0.34–0.99)	0.90 (0.57–1.23)	0.92 (0.62–1.14)	0.67 (0.50–0.97)	0.68 (0.41–1.03)	0.44 (0.17–0.74)	0.38 (0.11–0.67)	<.0001
Naïve, No. (%)	195 (27.4)	5 (6.7)	1 (2.2)	1 (1.7)	75 (23.0)	68 (45.9)	45 (76.3)	<.0001
CDC stage C, No. (%)	159 (22.3)	10 (13.3)	9 (20.0)	20 (33.3)	69 (21.2)	38 (25.7)	13 (22.0)	.07
HIV-RNA >50 copies/mL (experienced participants), No. (%)	95 (18.3)	6 (8.6)	1 (2.3)	22 (37.3)	39 (15.5)	24 (30.0)	3 (21.4)	<.0001
Years of ART (experienced participants), median (IQR)	9.8 (4.3–17.4)	10.8 (7.5–17.6)	12.1 (6.7–18.3)	13.5 (6.8–19.2)	7.9 (4.0–15.5)	9.2 (3.2–17.3)	9.1 (4.5–19.0)	.004
HCV active infection (baseline), No. (%)	66 (9.3)	2 (2.7)	2 (4.4)	7 (11.7)	27 (8.3)	25 (16.9)	3 (5.1)	.004
HCV eradication during follow-up (n = 66), No. (%)	30 (45.4)	0 (0)	1 (50.0)	3 (42.9)	15 (55.6)	10 (40.0)	1 (33.3)	.66
Statin use at baseline, No. (%)	65 (9.1)	11 (14.7)	7 (15.6)	9 (15.0)	26 (8.0)	9 (6.1)	3 (5.1)	.05
Statin started during the first year of observation (n = 648), No. (%)	17 (2.6)	2 (3.1)	3 (7.9)	2 (3.9)	6 (2.0)	3 (2.2)	1 (1.8)	.38

Table 1.

Open in new tab

Characteristics of 713 Participants in the SCOLTA Dolutegravir Cohort, According to Antiretroviral Regimen

	Total	3TC+DTG	RPV+DTG	PI+DTG	3TC/ABC/DTG	TDF/FTC+DTG	TAF/FTC+DTG
	n = 713	n = 75	n = 45	n = 60	n = 326	n = 148	n = 59	P
Sex M, No. (%)	533 (74.7)	59 (78.7)	26 (57.8)	45 (75.0)	244 (74.8)	111 (75.0)	48 (81.4)	.12
Age, mean ± SD, y	47.2 ± 11.6	50.6 ± 11.1	51.8 ± 10.8	50.4 ± 11.3	46.9 ± 11.5	45.0 ± 11.2	43.8 ± 12.4	<.0001
Caucasian, No. (%)	648 (90.9)	69 (92.0)	43 (95.6)	55 (91.7)	294 (90.2)	139 (93.9)	48 (81.4)	.09
Weight, mean ± SD, kg	70.5 ± 13.4	73.3 ± 13.9	70.2 ± 13.3	70.4 ± 11.5	69.8 ± 13.1	70.6 ± 14.6	71.4 ± 13.0	.46
BMI (n = 608), mean ± SD, kg/m²	24.2 ± 4.0	24.5 ± 3.5	25.0 ± 3.8	24.2 ± 3.5	24.0 ± 4.0	24.0 ± 4.2	24.7 ± 4.3	.61
Risk factor for HIV acquisition, No. (%)
Sexual	513 (72.0)	59 (78.7)	33 (73.3)	39 (65.0)	245 (75.2)	85 (57.4)	52 (88.1)
IVDU	112 (15.7)	8 (10.7)	11 (24.2)	14 (23.3)	42 (12.8)	32 (21.6)	5 (8.5)	<.0001
Other	88 (12.3)	8 (10.7)	1 (2.2)	7 (11.7)	39 (12.0)	31 (21.0)	2 (3.4)
CD4, mean ± SD, cells/mL	570 ± 367	725 ± 422	699 ± 318	614 ± 317	617 ± 359	419 ± 330	364 ± 312	<.0001
CD4/CD8 (n = 616), median (IQR)	0.64 (0.34–0.99)	0.90 (0.57–1.23)	0.92 (0.62–1.14)	0.67 (0.50–0.97)	0.68 (0.41–1.03)	0.44 (0.17–0.74)	0.38 (0.11–0.67)	<.0001
Naïve, No. (%)	195 (27.4)	5 (6.7)	1 (2.2)	1 (1.7)	75 (23.0)	68 (45.9)	45 (76.3)	<.0001
CDC stage C, No. (%)	159 (22.3)	10 (13.3)	9 (20.0)	20 (33.3)	69 (21.2)	38 (25.7)	13 (22.0)	.07
HIV-RNA >50 copies/mL (experienced participants), No. (%)	95 (18.3)	6 (8.6)	1 (2.3)	22 (37.3)	39 (15.5)	24 (30.0)	3 (21.4)	<.0001
Years of ART (experienced participants), median (IQR)	9.8 (4.3–17.4)	10.8 (7.5–17.6)	12.1 (6.7–18.3)	13.5 (6.8–19.2)	7.9 (4.0–15.5)	9.2 (3.2–17.3)	9.1 (4.5–19.0)	.004
HCV active infection (baseline), No. (%)	66 (9.3)	2 (2.7)	2 (4.4)	7 (11.7)	27 (8.3)	25 (16.9)	3 (5.1)	.004
HCV eradication during follow-up (n = 66), No. (%)	30 (45.4)	0 (0)	1 (50.0)	3 (42.9)	15 (55.6)	10 (40.0)	1 (33.3)	.66
Statin use at baseline, No. (%)	65 (9.1)	11 (14.7)	7 (15.6)	9 (15.0)	26 (8.0)	9 (6.1)	3 (5.1)	.05
Statin started during the first year of observation (n = 648), No. (%)	17 (2.6)	2 (3.1)	3 (7.9)	2 (3.9)	6 (2.0)	3 (2.2)	1 (1.8)	.38

	Total	3TC+DTG	RPV+DTG	PI+DTG	3TC/ABC/DTG	TDF/FTC+DTG	TAF/FTC+DTG
	n = 713	n = 75	n = 45	n = 60	n = 326	n = 148	n = 59	P
Sex M, No. (%)	533 (74.7)	59 (78.7)	26 (57.8)	45 (75.0)	244 (74.8)	111 (75.0)	48 (81.4)	.12
Age, mean ± SD, y	47.2 ± 11.6	50.6 ± 11.1	51.8 ± 10.8	50.4 ± 11.3	46.9 ± 11.5	45.0 ± 11.2	43.8 ± 12.4	<.0001
Caucasian, No. (%)	648 (90.9)	69 (92.0)	43 (95.6)	55 (91.7)	294 (90.2)	139 (93.9)	48 (81.4)	.09
Weight, mean ± SD, kg	70.5 ± 13.4	73.3 ± 13.9	70.2 ± 13.3	70.4 ± 11.5	69.8 ± 13.1	70.6 ± 14.6	71.4 ± 13.0	.46
BMI (n = 608), mean ± SD, kg/m²	24.2 ± 4.0	24.5 ± 3.5	25.0 ± 3.8	24.2 ± 3.5	24.0 ± 4.0	24.0 ± 4.2	24.7 ± 4.3	.61
Risk factor for HIV acquisition, No. (%)
Sexual	513 (72.0)	59 (78.7)	33 (73.3)	39 (65.0)	245 (75.2)	85 (57.4)	52 (88.1)
IVDU	112 (15.7)	8 (10.7)	11 (24.2)	14 (23.3)	42 (12.8)	32 (21.6)	5 (8.5)	<.0001
Other	88 (12.3)	8 (10.7)	1 (2.2)	7 (11.7)	39 (12.0)	31 (21.0)	2 (3.4)
CD4, mean ± SD, cells/mL	570 ± 367	725 ± 422	699 ± 318	614 ± 317	617 ± 359	419 ± 330	364 ± 312	<.0001
CD4/CD8 (n = 616), median (IQR)	0.64 (0.34–0.99)	0.90 (0.57–1.23)	0.92 (0.62–1.14)	0.67 (0.50–0.97)	0.68 (0.41–1.03)	0.44 (0.17–0.74)	0.38 (0.11–0.67)	<.0001
Naïve, No. (%)	195 (27.4)	5 (6.7)	1 (2.2)	1 (1.7)	75 (23.0)	68 (45.9)	45 (76.3)	<.0001
CDC stage C, No. (%)	159 (22.3)	10 (13.3)	9 (20.0)	20 (33.3)	69 (21.2)	38 (25.7)	13 (22.0)	.07
HIV-RNA >50 copies/mL (experienced participants), No. (%)	95 (18.3)	6 (8.6)	1 (2.3)	22 (37.3)	39 (15.5)	24 (30.0)	3 (21.4)	<.0001
Years of ART (experienced participants), median (IQR)	9.8 (4.3–17.4)	10.8 (7.5–17.6)	12.1 (6.7–18.3)	13.5 (6.8–19.2)	7.9 (4.0–15.5)	9.2 (3.2–17.3)	9.1 (4.5–19.0)	.004
HCV active infection (baseline), No. (%)	66 (9.3)	2 (2.7)	2 (4.4)	7 (11.7)	27 (8.3)	25 (16.9)	3 (5.1)	.004
HCV eradication during follow-up (n = 66), No. (%)	30 (45.4)	0 (0)	1 (50.0)	3 (42.9)	15 (55.6)	10 (40.0)	1 (33.3)	.66
Statin use at baseline, No. (%)	65 (9.1)	11 (14.7)	7 (15.6)	9 (15.0)	26 (8.0)	9 (6.1)	3 (5.1)	.05
Statin started during the first year of observation (n = 648), No. (%)	17 (2.6)	2 (3.1)	3 (7.9)	2 (3.9)	6 (2.0)	3 (2.2)	1 (1.8)	.38

Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BMI, body mass index; CDC, Centers for Disease Control and Prevention; DTG, dolutegravir; FTC, emtricitabine; HCV, hepatitis C virus; IQR, interquartile range; IVDU, intravenous drug use; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); SCOLTA, Surveillance Cohort Long-Term Toxicity Antiretrovirals; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

This Feature Is Available To Subscribers Only